MYC and plasma cell myeloma: Artesunate has earlier been shown to overcome bortezomib resistance in myeloma cells in vitro [32] and to have growth suppressive properties in primary myeloma cells and in myeloma and lymphoma cell lines by inducing apoptosis concomitant with downregulation of MYC [33].